FDA Approves BUPRENORPHINE HCL — SpecGx LLC

On December 10, 2025, SpecGx LLC received FDA approval for the generic sublingual tablet formulation of Buprenorphine Hydrochloride (ANDA 218473), a significant development that is poised to reduce costs for payers and expand access to this essential treatment. This approval establishes SpecGx as a key competitor in the generic opioid dependence market, likely intensifying pricing pressure for branded alternatives and automating a substantial revenue stream.